Valganciclovir
- TRADE NAME: Valcyte (Roche)
- INDICATIONS: Cytomegalovirus retinitis (CMV) in patients with AIDS, prevention of CMV disease in high-risk transplant patients
- CLASS: Antiviral, Guanine nucleoside analog
- HALF-LIFE: 4 hours (in severe renal impairment up to 68%)
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Abacavir, Cobicistat/Elvitegravir/Emtricitabine/Tenofovir Alafenamide, Cobicistat/Elvitegravir/Emtricitabine/Tenofovir Disoproxil, Emtricitabine, Tenofovir Disoproxil
PREGNANCY CATEGORY: N/A
May cause fetal toxicity based on findings in animal studies
Valganciclovir is rapidly converted to ganciclovir in the body.
HEMATOLOGIC TOXICITY, IMPAIRMENT OF FERTILITY, FETAL TOXICITY, MUTAGENESIS AND CARCINOGENESIS
See full prescribing information for complete boxed warning.
Please login to see the rest of this drug profile
SKIN
MUCOSAL
CENTRAL NERVOUS SYSTEM
GASTROINTESTINAL/HEPATIC
HEMATOLOGIC
NEUROMUSCULAR/SKELETAL
OCULAR
OTHER
Page last updated 07/27/2019
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
